FDA panel details cross‑center programs to help small‑population drug and device development
FDA speakers from CDER, CBER, CDRH and the Rare Disease Innovation Hub described educational programs (LEADER3D), patient listening meetings, manufacturing flexibilities, and workshops (RISE) to help developers design feasible trials and integrate patient voices into endpoints and long‑term follow‑up.
The full story
FDA center staff used Rare Disease Day panels to outline practical programs and resources aimed at making rare‑disease product development more feasible and patient‑centered. CDER’s LEADER3D educational initiative provides case studies, videos and a user guide to help developers understand regulatory requirements; a public docket is open for feedback. CBER described patient listening meetings used in 2024 that shaped draft guidance on post‑approval methods and long‑term follow‑up for cell and gene therapies; speakers emphasized telehealth options and decentralized registries to reduce long‑term follow‑up burden. CDRH discussed device pathways (breakthrough, Humanitarian Use Device, MDDT) and the use of patient‑generated health data and digital health technologies to decentralize trials.
Sign up to keep reading.
Your free newsletter brings you what your city council, county, and school board discussed and decided.